Login to Your Account



Dyax Signs Potential $106M Japanese Deal for HAE Drug

By Jennifer Boggs


Friday, October 1, 2010
As Dyax Corp. continues ramping up sales of hereditary angioedema (HAE) drug Kalbitor (ecallantide) in the U.S., the biotech is expanding the drug's reach into Japan thanks to a potential $106 million deal with CMIC Co. Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription